DETERMINANTS OF SURVIVAL IN IDIOPATHIC PULMONARY FIBROSIS

被引:257
|
作者
SCHWARTZ, DA
HELMERS, RA
GALVIN, JR
VANFOSSEN, DS
FREES, KL
DAYTON, CS
BURMEISTER, LF
HUNNINGHAKE, GW
机构
[1] VET ADM MED CTR,DEPT INTERNAL MED,DIV PULM DIS,IOWA CITY,IA 52240
[2] VET ADM MED CTR,DEPT RADIOL,IOWA CITY,IA
关键词
D O I
10.1164/ajrccm.149.2.8306044
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
To identify the determinants of survival in patients with idiopathic pulmonary fibrosis (IPF), we performed a survival analysis on 74 subjects with IPF. The study subjects were on average 64 yr of age (range, 25 to 83 yr), 62% were male, and 29% were never smokers. A tissue diagnosis was made in 67 (91%) of our study subjects. These subjects were followed for a mean period of 4 yr (range, 1.4 to 118.8 months) after the onset of pulmonary symptoms. During the period of observation, 41 subjects died (median survival = 28.2 months) and 33 continue to survive (median follow-up period = 60.9 months). A univariate analysis demonstrated that diminished survival was significantly associated with male gender (hazard ratio = 1.98; 95% confidence interval [CI] = 1.01-3.85), a higher FEV(1)/FVC ratio (hazard ratio = 1.82 [per 10% increase in the FEV(1)/FVC ratio]; 95% CI = 1.21-2.73), a lower percent predicted FVC (hazard ratio = 0.74; 95% CI = 0.60-0.91), a lower percent predicted total lung capacity (TLC) (hazard ratio = 0.75; 95% CI = 0.60-0.94), a lower percent predicted diffusing capacity of carbon monoxide (DL(CO)) (hazard ratio = 0.69; 95% CI = 0.53-0.89), a higher ILO profusion category on chest radiograph (hazard ratio = 3.52; 95% CI = 1.58-7.87), and an enhanced release of prostaglandin E(2) (PGE(2)) by cultured alveolar macrophages (hazard ratio = 1.32 [per 10 pm/ml of PGE(2)]; 95% CI = 1.07-1.62). In fact, after controlling for age, Cox's regression analyses demonstrated that diminished survival was independently associated with male gender (hazard ratio = 9.05; 95% CI = 1.84-44.5), a higher FEV(1)/FVC ratio (hazard ratio = 3.91 [per 10% increase in the FEV(1)/FVC ratio]; 95% CI = 1.68-8.07), and an enhanced release of PGE(2) by cultured alveolar macrophages (hazard ratio = 1.45 [per 10 pm/ml of PGE(2)]; 95% CI = 1.14-1.83). Survival was not found to be independently associated with the concentration of cells in the ravage fluid or other cytokines (tumor necrosis factor alpha [TNF alpha] and interleukin-1 beta [IL-1 beta]) released by alveolar macrophages. Limiting our analysis to subjects closely followed in our SCOR Program (n = 41), Cox's regression analysis (adjusted for age) demonstrated that diminished survival was independently associated with male gender (hazard ratio = 8.21; 95% CI = 1.30-50.6), a higher ILO profusion category (hazard ratio = 4.00; 95% CI = 1.43-11.42), and a lower concentration of lymphocytes in bronchoalveolar ravage fluid (hazard ratio = 0.95; 95% CI = 0.91-0.99). In aggregate, our findings suggest that adverse prognosticators in IPF include male gender, advanced disease (restrictive lung function, abnormal gas exchange, and increased interstitial abnormalities on the chest radiograph), and, possibly, increased release of PGE(2) from cultured alveolar macrophages.
引用
收藏
页码:450 / 454
页数:5
相关论文
共 50 条
  • [21] Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis
    Ley, Brett
    Collard, Harold R.
    King, Talmadge E., Jr.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (04) : 431 - 440
  • [22] Predictive factors for survival in patients with idiopathic pulmonary fibrosis
    Casanova, Alvaro
    Maria Giron, Rosa
    Molina, Maria
    Xaubet, Antonio
    Ancochea, Julio
    MEDICINA CLINICA, 2009, 133 (09): : 333 - 336
  • [23] Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis
    Kalafatis, Dimitrios
    Carlson, Lisa
    Gao, Jing
    Li, Chuan Xing
    Pesonen, Ida
    Skold, Carl Magnus
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [24] Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
    Karkkainen, Miia
    Kettunen, Hannu-Pekka
    Nurmi, Hanna
    Selander, Tuomas
    Purokivi, Minna
    Kaarteenaho, Riitta
    RESPIRATORY RESEARCH, 2017, 18
  • [25] PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
    Oldham, Justin M.
    Allen, Richard J.
    Lorenzo-Salazar, Jose M.
    Molyneaux, Philip L.
    Ma, Shwu-Fan
    Joseph, Chitra
    Kim, John S.
    Guillen-Guio, Beatriz
    Hernandez-Beeftink, Tamara
    Kropski, Jonathan A.
    Huang, Yong
    Lee, Cathryn T.
    Adegunsoye, Ayodeji
    Pugashetti, Janelle Vu
    Linderholm, Angela L.
    Vo, Vivian
    Strek, Mary E.
    Jou, Jonathan
    Munoz-Barrera, Adrian
    Rubio-Rodriguez, Luis A.
    Hubbard, Richard
    Hirani, Nik
    Whyte, Moira K. B.
    Hart, Simon
    Nicholson, Andrew G.
    Lancaster, Lisa
    Parfrey, Helen
    Rassl, Doris
    Wallace, William
    Valenzi, Eleanor
    Zhang, Yingze
    Mychaleckyj, Josyf
    Stockwell, Amy
    Kaminski, Naftali
    Wolters, Paul J.
    Molina-Molina, Maria
    Banovich, Nicholas E.
    Fahy, William A.
    Martinez, Fernando J.
    Hall, Ian P.
    Tobin, Martin D.
    Maher, Toby M.
    Blackwell, Timothy S.
    Yaspan, Brian L.
    Jenkins, R. Gisli
    Flores, Carlos
    Wain, Louise V.
    Noth, Imre
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (11) : 1515 - 1524
  • [26] The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis
    Tomassetti, Sara
    Gurioli, Christian
    Ryu, Jay H.
    Decker, Paul A.
    Ravaglia, Claudia
    Tantalocco, Paola
    Buccioli, Matteo
    Piciucchi, Sara
    Sverzellati, Nicola
    Dubini, Alessandra
    Gavelli, Giampaolo
    Chilosi, Marco
    Poletti, Venerino
    CHEST, 2015, 147 (01) : 157 - 164
  • [27] Idiopathic pulmonary fibrosis - Predicting response to therapy and survival
    Gay, SE
    Kazerooni, EA
    Toews, CB
    Lynch, JP
    Gross, BH
    Cascade, PN
    Spizarny, DL
    Flint, A
    Schork, MA
    Whyte, RI
    Popovich, J
    Hyzy, R
    Martinez, FJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (04) : 1063 - 1072
  • [28] Surfactant protein a predicts survival in idiopathic pulmonary fibrosis
    McCormack, FX
    Mason, RJ
    Bartelson, BB
    King, TE
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (03) : 825 - 826
  • [29] Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
    Habiel, David M.
    Hogaboam, Cory
    FRONTIERS IN PHARMACOLOGY, 2014, 5
  • [30] Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
    Miia Kärkkäinen
    Hannu-Pekka Kettunen
    Hanna Nurmi
    Tuomas Selander
    Minna Purokivi
    Riitta Kaarteenaho
    Respiratory Research, 18